Drug intelligence / Profile preview

Montanide ISA 720 (Seppic)

Development stage: Unknown
Lead developer: Bavarian Nordic
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular, Subcutaneous, Intradermal, Intraperitoneal, Parenteral

Overview

Montanide ISA 720 is a proprietary water-in-oil vaccine-emulsion adjuvant manufactured by Seppic. It comprises a metabolizable non-mineral oil phase and a refined mannide monooleate-family emulsifier. When combined with an antigen-containing aqueous phase, it forms a depot at the injection site that can slow antigen release and enhance antigen-specific cellular and humoral immune responses. It was evaluated as an adjuvant for the investigational MVA-BN yellow fever vaccine in a completed Phase 1 NIAID-sponsored study in healthy adults.

Brand names: Montanide ISA 720Montanide ISA 720 VG
Other names: ISA 720ISA720ISA-720Montanide ISA-720

Beyond the preview

Go deeper on Montanide ISA 720 (Seppic).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Montanide ISA 720 (Seppic).

Explore the full profile